Here are a few comments for your consideration:
a)Yes, according to the company policy the payout ratio is between 50% and 80%, so the maximum "error" in the payment can be 8/5=1.6
b)In reality for the past several years since FY19 the payout ratio has not been below 70%, so the above mentioned error is reduced to 8/7=1.14 or only 14%only.
c)Now we will take into a consideration an error made by PilbaraBoy with a statement of “FMG receive approx 85-90%”. As per the information from http://www.custeel.com/en/csi.jspwe have that the average 62% Fe fines IOP since 1 January 2022 has been ~US$142.
A full production cost in the past was ~US$41. So based on the 70% (from recent company reports) and 90% (from PilbaraBoy post) rates we have the following figures for the profit:
70% => US$99.4-US$41=US$58.4
90% => US$127.8-US$41=US$86.7
86.7/58.4>1.48 or over 48% error
So in summary as you can see an error in the rate for the IOP for 62% Fe is significantly larger that an error in the realistic payout ratio.
- Forums
- ASX - By Stock
- FMG
- next dividend
next dividend, page-58
-
- There are more pages in this discussion • 185 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FMG (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.62 |
Change
0.645(3.40%) |
Mkt cap ! $59.57B |
Open | High | Low | Value | Volume |
$19.11 | $19.66 | $19.11 | $103.9M | 5.377M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 2976 | $19.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.62 | 13880 | 20 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 8705 | 19.630 |
16 | 5988 | 19.620 |
16 | 7777 | 19.610 |
13 | 6285 | 19.600 |
9 | 4724 | 19.590 |
Price($) | Vol. | No. |
---|---|---|
19.640 | 4081 | 9 |
19.650 | 7549 | 18 |
19.660 | 8419 | 15 |
19.670 | 11017 | 12 |
19.680 | 18983 | 22 |
Last trade - 14.36pm 10/10/2024 (20 minute delay) ? |
Featured News
LU7
The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
FMG (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online